New hope for lung cancer: experimental drug SHR-1826 enters phase 2 trial
NCT ID NCT07489716
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a new drug called SHR-1826 in 90 people with advanced non-small cell lung cancer that has worsened after other treatments. Participants receive the drug by IV every three weeks. The study aims to see if the drug can shrink tumors and how safe it is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-1826
What this could lead to
If successful, this could provide a new treatment option for people with advanced non-small cell lung cancer who have not responded to other therapies.
What could go wrong
This is an early-phase trial with only 90 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, Shandong, 250117, China
Contact